Bioharvest Sciences Inc. income statement BHST
In fiscal 2025, which ended Dec 31, 2025, Bioharvest Sciences Inc. reported revenue of $34.5 million, up 37.0% from the year before. It recorded a net loss of $11.1 million. The operating loss came to $5.6 million, an operating margin of -16.2%.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
|---|---|---|
| Revenue |
35
+37.0%
|
25
|
| Cost of revenue |
14
+24.8%
|
11
|
| Gross profit |
20
+46.9%
|
14
|
| Research and development |
5
+10.7%
|
5
|
| Selling, general and administrative |
21
+28.5%
|
16
|
| Operating expenses |
26
+24.5%
|
21
|
| Operating income |
-6
+20.2%
|
-7
|
| Pretax income |
-11
+14.3%
|
-13
|
| Income tax |
-0
-850.0%
|
-0
|
| Net income |
-11
+13.8%
|
-13
|
| Basic EPS |
-0.60
+25.0%
|
-0.80
|
| Other measures | ||
| Depreciation and amortization |
2
+29.8%
|
1
|
| EBITDA |
-4
+31.1%
|
-6
|
| Margins | ||
| Gross margin |
59.34%
|
55.35%
|
| Operating margin |
-16.16%
|
-27.75%
|
| Pretax margin |
-32.05%
|
-51.23%
|
| Profit margin |
-32.27%
|
-51.27%
|
| EBITDA margin |
-11.45%
|
-22.78%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1723464
- Former names
- CANNA-V-CELL SCIENCES INC. (until Apr 21, 2020); Midnight Star Ventures Corp. (until Oct 15, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.